SNMMI continues advocacy on utility of amyloid imaging

03/27/2013 | MolecularImaging.net

SNMMI and the Alzheimer's Association will meet with CMS officials next month to discuss appropriate use criteria concerning the use of amyloid imaging in evaluating and diagnosing Alzheimer's disease. SNMMI President Frederic H. Fahey said SNMMI "will recommend coverage for the three indications specified by the AUC." Amyloid imaging is not currently reimbursed.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY